NCT02535078 - Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | Biotech Hunter

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 19, 2023

Study Completion Date

September 6, 2023

Conditions

Malignant Melanoma

Interventions

DRUG

Tebentafusp (IMCgp100)

soluble gp100-specific T cell receptor with anti-CD3 scFV

Trial Locations (4)

Memorial Sloan Kettering Cancer Center, New York

University of Pittsburgh Medical Center, Pittsburgh

Thomas Jefferson University Hospital, Philadelphia

The Angeles Clinic and Research Institute, Los Angeles